Kiniksa Pharmaceuticals

Biotechnology
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

$3.3B

Market Cap • 1/8/2026

2015

(11 years)

Founded

2018

(8 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country